NDA Accepted for OnceWeekly Injectable Diabetes DrugJody A. Charnow, Editor
Tumour Risk with Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus Patients: A Systematic Review Once-weekly glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a novel class of injectable antidiabetic drugs. Previous studies indicated that GLP-1R... X Guo,...
Previous evidence suggests that once-weekly insulin dosing regimens are viewed positively by people with type 2 diabetes16; a study of injectable glucagon-like peptide 1 receptor agonists demonstrated that once-weekly treatments for type 2 diabetes may improve treatment adherence and persistence compared...
have type 2 diabetes and a history of diabetic retinopathy have or have had depression, suicidal thoughts, or mental health issues are pregnant or plan to become pregnant. Wegovy ® may harm your unborn baby. You should stop using Wegovy ® 2 months before you plan to become pregnant a...
J Diabetes Investig. 2022;13(1):65–73. Article CAS Google Scholar Kaku K, Yamada Y, Watada H, et al. Safety and efficacy of once-weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: a randomized trial. Diabetes Obes ...
- 《Diabetes Metabolic Syndrome & Obesity Targets & Therapy》 被引量: 26发表: 2015年 Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients Exenatide once weekly (QW) is a glucagon-like peptide-1 receptor agonist (GLP-1RA)...
Diabetes drugs: metformin 0 (0.0) 1 (6.3) 2 (14.3) 3 (7.3) Lipid-modifying agents: atorvastatin calcium 1 (9.1) 2 (12.5) 0 (0.0) 3 (7.3) Psychotropics Lorazepam 2 (18.2) 2 (12.5) 2 (14.3) 6 (14.6) Quetiapine 0 (0.0) 1 (6.3) 3 (21.4) 4 (9.8) Risperidone 0 (0.0) 2 ...
FDA approves once-weekly GLP-1 injectable for type 2 diabetesFDA approved albiglutide (Tanzeum, GlaxoSmithKline), a once-weekly subcutaneous injectable for the treatment of adults with ...
Weekly InjectableAims: To understand patient preferences for once-daily oral vs. once-weekly injectable Type 2 Diabetes Mellitus (T2DM) medication administration profiles, and reasons for their preferences. Materials and methods: The REVISE study, a cross-sectional online survey of 600 participants ...
doi:10.1016/j.jval.2020.08.022K. BoyeM. RossR. ModyM. KonigH. GelhornValue in Health